MA42546A - Combinaisons d'inhibiteur de la tyrosine kinase de bruton et leurs utilisations - Google Patents

Combinaisons d'inhibiteur de la tyrosine kinase de bruton et leurs utilisations

Info

Publication number
MA42546A
MA42546A MA042546A MA42546A MA42546A MA 42546 A MA42546 A MA 42546A MA 042546 A MA042546 A MA 042546A MA 42546 A MA42546 A MA 42546A MA 42546 A MA42546 A MA 42546A
Authority
MA
Morocco
Prior art keywords
tyrosine kinase
kinase inhibitor
bruton tyrosine
inhibitor combinations
combinations
Prior art date
Application number
MA042546A
Other languages
English (en)
Inventor
Betty Chang
Jun Chen
Ssucheng Jeff Hsu
Yujun Huang
Danelle James
Taisei Kinoshita
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of MA42546A publication Critical patent/MA42546A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
MA042546A 2015-07-31 2016-07-29 Combinaisons d'inhibiteur de la tyrosine kinase de bruton et leurs utilisations MA42546A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562199852P 2015-07-31 2015-07-31
US201562221499P 2015-09-21 2015-09-21
US201562243432P 2015-10-19 2015-10-19

Publications (1)

Publication Number Publication Date
MA42546A true MA42546A (fr) 2018-06-06

Family

ID=57885762

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042546A MA42546A (fr) 2015-07-31 2016-07-29 Combinaisons d'inhibiteur de la tyrosine kinase de bruton et leurs utilisations

Country Status (10)

Country Link
US (2) US20170027941A1 (fr)
EP (1) EP3328380A4 (fr)
JP (1) JP2018522028A (fr)
CN (1) CN108024996A (fr)
AU (1) AU2016303659A1 (fr)
BR (1) BR112018002139A2 (fr)
CA (1) CA2994161A1 (fr)
MA (1) MA42546A (fr)
MX (1) MX2018001369A (fr)
WO (1) WO2017023815A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
TW201922256A (zh) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
CN111053777A (zh) * 2018-10-16 2020-04-24 正大天晴药业集团股份有限公司 伊布替尼的药物组合物及其应用
CN111419853B (zh) * 2020-05-27 2022-07-19 德立唯（北京）生物科技有限公司 一种治疗乳腺癌的葫芦素与依鲁替尼组合物
US11433072B1 (en) * 2021-06-10 2022-09-06 Hikma Pharmaceuticals USA, Inc. Oral dosage forms of ibrutinib

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101415409B (zh) * 2006-04-05 2012-12-05 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
SG186109A1 (en) * 2010-06-02 2013-01-30 Abraxis Bioscience Llc Methods of treating bladder cancer
CA3007787C (fr) * 2010-06-03 2020-03-10 Pharmacyclics Llc Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk)
CA2890111A1 (fr) * 2012-11-02 2014-05-08 Pharmacyclics, Inc. Therapie adjuvante par inhibiteur de kinase de la famille tec
MX369503B (es) * 2013-04-08 2019-11-11 Pharmacyclics Llc Combinaciones que comprenden ibrutinib y abt-199 para tratar trastornos proliferativos de células b y métodos de uso de las mismas.
EP2832358A1 (fr) * 2013-08-02 2015-02-04 Bionsil S.r.l. Kit pharmaceutique pour utilisation dans le traitement de cancer du côlon et colorectal
US9415050B2 (en) * 2013-08-12 2016-08-16 Pharmacyclics Llc Methods for the treatment of HER2 amplified cancer
JP2016537345A (ja) * 2013-11-13 2016-12-01 ノバルティス アーゲー 免疫応答を増強するためのｍＴＯＲ阻害剤
WO2016123504A1 (fr) * 2015-01-30 2016-08-04 Pharmacyclics Llc Combinaisons d'inhibiteur btk et multirésistance aux médicaments

Also Published As

Publication number Publication date
CA2994161A1 (fr) 2017-02-09
EP3328380A1 (fr) 2018-06-06
EP3328380A4 (fr) 2019-07-24
US20200030330A1 (en) 2020-01-30
BR112018002139A2 (pt) 2018-09-11
MX2018001369A (es) 2018-11-29
JP2018522028A (ja) 2018-08-09
CN108024996A (zh) 2018-05-11
WO2017023815A1 (fr) 2017-02-09
AU2016303659A1 (en) 2018-02-22
US20170027941A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
MA50618A (fr) Polyrhérapies et leurs utilisations
MA42623A (fr) Inhibiteurs de la tyrosine kinase de bruton
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA43821A (fr) Pyrimidines et variantes de celles-ci, et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
MA43162A (fr) Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton
MA51287A (fr) Analogues d'incrétine et leurs utilisations
MA42242A (fr) Inhibiteurs de la tyrosine kinase
MA53400A (fr) Hétéromultimères alk7: actriib et leurs utilisations
MA41460A (fr) Agents de liaison à la tnfrsf et leurs utilisations
MA41350A (fr) Synthèse d'un inhibiteur de la tyrosine kinase de bruton
MA43308A (fr) Molécules d'anticorps se liant à april et leurs utilisations
BR112017002232A2 (pt) combinações de inibidor de tirosina quinase de bruton e usos das mesmas
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
ZA201805439B (en) Bruton's tyrosine kinase inhibitors
EP3414234A4 (fr) Inhibiteurs de la tyrosine kinase de bruton
MA51288A (fr) Analogues d'incrétine et leurs utilisations
MA44489A (fr) Pyrimidines et variants de celles-ci, et leurs utilisations
KR102068915B9 (ko) 조직 인자 경로 억제제 항체 및 그의 용도
MA44262A (fr) Bioconjugués et utilisations de ceux-ci
IL287433A (en) Combination of anti-cd19 antibody and proton tyrosine kinase inhibitor and its uses
MA43567A (fr) Anticorps pacap et leurs utilisations
HK1243929A1 (zh) Tlr抑制劑和布魯頓酪氨酸激酶抑制劑組合
MA42546A (fr) Combinaisons d'inhibiteur de la tyrosine kinase de bruton et leurs utilisations
MA46945A (fr) Exopolysaccharides et leurs utilisations